DEVA "Doktorlar Ecza ve Alat" (Physcians Drugs and Equipment) Sanayi ve Ticaret A.Ş. was incorporated.
The first manufacturing facility is established in Tünel, Beyoğlu.
Bomonti pharmaceutical plant was opened.
The ampoule plant was set up.
The production of Tetracycline and Oxytetracycline was realized as the first pharmaceutical raw material in Turkey. The title and status of the Company was changed from DEVA "Doktorlar Ecza ve Alat" (Physicians Drugs and Equipment) Sanayi ve Ticaret Anonim Şirketi to DEVA Holding A.Ş.
The largest pharmaceutical manufacturing facility was purchased from Farmitalia.
Carlo Erba pharmaceutical plant was purchased.
With the production of Gentamicine in its active pharmaceutical ingredient manufacturing facilities, it was listed among 5 establishments to produce this active ingredient throughout the world.
A detergent and cologne factory was set up in İzmit.
The shares of DEVA Holding started to be traded on the Istanbul Stock Exchange.
The production of lincomycin (antibiotic) was started at the "pharmaceutical active ingredient" manufacturing facilities.
The foundation of the synthesis plant were laid in Çerkezköy.
ANSA A.Ş. was purchased by DEVA Holding, the title of the firm was changed as DEPA A.Ş. With the production of Potassium Clavulanate, the company accomplished being one of only five establishments in the world capable of producing this active ingredient.
DEVA Holding ranked among the top 10 pharmaceutical companies of Turkey with USD 120 million sales on box basis and a market share of 4,6%. The equity capital of the company was increased to TRY 48 million. Amoklavin became the best selling drug of the year in Turkey.
The majority ownership of DEVA Holding was transferred to EastPharma Limited, a business venture of GEM Global Equities Management S.A. In connection with this restructuring, Phillip Haas was elected as the new Chairman of the Board of Directors in July 2006.
The company headquarters moved to its new building in Halkalı. Production plant construction was started in çerkezköy and Köseköy İzmit. Representative offices were opened in Georgia, Russia (Moscow), Azerbaijan and Uzbekistan.
50 years of success in the sector was celebrated together with doctors and pharmacists all around Turkey.
R&D center “DEVARGE” was established.
Transition to SAP ERP system was successfully completed.
DEVA signed the AP Contract on Nov 30, 2010 for the takeover of Production Facility at Çerkezköy Organized Ind. Zone – Tekirdağ owned by Zentiva, engaged in manufacturing drug substance with an area of 67.551 m2 with closed area of 18.742 m2 with royalty for manufacture, sales and export of some drug substances manufactured at said Production Facility and 61 personnel working at aforementioned plant together with entire machinery and equipment including all rights.
Transactions as to merger of DEVA Holding with DEVA İlaç Sanayi ve Ticaret A.Ş. by takeover was completed as of December 31, 2010. Due to such merger, its issued capital was increased from 180.000.000 TL to 180.070.656 TL within its registered authorized stock and the entire amount was given to partners of DEVA İlaç Sanayi ve Ticaret A.Ş. apart from DEVA Holding. This merger served the purpose of reaching a more efficient business model and of operational cost saving.
Turkey’s leading drug manufacturer DEVA Holding delivered drug aid package of 412.3 thousand Turkish Liras composed of 31 palettes to Save the Children Germany Organization. Drug aid package to be used to heal the wounds of flood victims and composed of 62.6 thousand of DEVA drugs shall be conveyed by Save The Children Organization to those in need.
DEVA Holding, the leading drug manufacturer in Turkey, delivered its aid package consisting of 1.581 parcels of medicine worth a total of 2.4 million Turkish Liras to the Turkish Red Crescent Society in October and 1.355 parcels to be used to heal the wounds of Pakistan’s flood victims and containing DEVA pharmaceuticals will be distributed to those in need by the Turkish Red Crescent Society. Moreover, it supported Turkish Red Crescent through blood donation over 120 units.
In 2010, DEVA Holding joins with DEVA İlaç Sanayi ve Ticaret A.Ş.
During the ceremony held on February 26, 2011 to grant certificates of R&D Center within the scope of law numbered 5746 and executed by the Ministry of Industry and Trade; Republic of Turkey, DEVA Holding was granted the Certificate of “R&D Center” by The Esteemed Prime Minister Tayyip Erdogan.
DEVA Holding released its product providing cure for allergic skin disease named atopic dermatitis (AD) and atopic eczema (AE) in February. AE detected during childhood by 10-29% is observed by 1-3% in adults while it is more frequently encountered in developed and developing countries. The product manufactured by DEVA Holding in forms of syrup and capsule and as natural dietary supplement was released into service of Turkish Medicine in February.
DEVA's capital increased to 200.000.000 TRY
At the end of 2011, 42 new product development projects have been completed.
In 2012, production facilities of DEVA Holding audited by German Ministry of Health last month received approval of compliance with European GMP (Good Manufacturing Practice)
In 2012, first registration application to FDA has been realized.
2013 Registered supplier of UN. DEVA was deemed worthy of the first prize in the “R&D Study of the Year” branch of the Golden Mortar competition.
Inhaler manufacturing site opened. FDA ANDA submission 107 approval in 19 countries inc. Germany, Switzerland, Holland, Australia, New Zeland
DEVA was selected as the Best R&D Company by the Turkish Ministry of Science, Technology and Industry.
DEVA, was selected as the Best R&D Company by Eczacı Magazine.
DEVA gained foothold in Germany with Devatis.
Vetaş merged with DEVA Holding.
Kartepe Manufacturing Plant received FDA approval.
DEVA Cerkezköy II Manufacturing Facility has received FDA approval
The first time products exported to USA
DEVA was awarded the best AR-GE award by Golden Havan with the work of the lenolidomide.


Established in 1958, DEVA Holding is one of the well-established pharmaceutical companies in Turkey.

With the main area of operations including manufacturing and marketing medicinal products for human and use and raw materials, DEVA Holding also manufactures veterinary medicines, eau de Cologne, and medical ampoules.

The majority of shares in DEVA Holding was acquired in 2006 by funds managed by GEM Global Equities Management S.A., an international fund management company, and EastPharma Ltd. was established to assume management.

DEVA holding is pacing rapidly toward its goal of being the first choice by offering innovative and unique products with a high-quality experience by creating giant pharmaceutical brands in areas where it competes, in order to make healthy living accessible to everyone around the world. DEVA Holding places new products on the market every year to diversify its offering and make a difference. Currently, DEVA Holding has approximately 400 products in its portfolio, spanning 13 different therapeut fields, ranging from oncology to cardiology and from the respiratory system to ophthalmology.

With progressively expanding regional growth and export operations, DEVA Holding is the holder of more than 500 marketing authorizations in over 50 countries, including the USA, Switzerland, Germany, Netherlands and the UK.

DEVA Holding focuses on research and development to improve access to medicines for patients who need them, and its manufacturing facilities are certified compliant with the European GMP (Good Manufacturing Practice) and the US FDA (Food and Drug Administration) requirements, with the first export to the USA already accomplished.

DEVA Holding develops high added value, innovative new forms and products with its highly-competent staff of experts trained in their areas and experienced in R&D in its full-fledged laboratories and manufacturing areas equipped with state-of-the-art technology at its award-winning DEVARGE Center.

With its manufacturing capabilities, DEVA Holding has become the domestic corporation with the most comprehensive production capabilities in Turkey. Undertaking manufacturing operations at facilities in Çerkezköy and Kartepe, DEVA Holding holds an annual output capacity of 515 million units of medicines.

Continuing to work for a healthier future, DEVA Holding also supports social responsibility projects.

Notes From The Pharmaceutical Industry

According to free market and overall tender data of IMS Health, 2,387 million units and TL 26.4 billion (*) worth of medicines were sold in Turkish Pharmaceutical Market in 2017. The market achieved growth at a rate of 3.92% in number of units and at a rate of 20.50% in TL compared with the previous year.

Rate of prescription drugs to total pharmaceutical market in Turkish market is 93.3% in number of units and 92.8% in TL.

Although drugs from many treatment groups are imported in our country, preparations requiring new and advanced technology, nervous system drugs, blood factors, some controlled-release drugs, insulin, and anti-cancer drugs are predominantly imported.

According to IMS Health data, the sector’s import increased by 6% on a unit basis and decreased by 0.7%, resulting in USD 4.1 billion on USD basis in 2017. The domestic pharmaceutical market grew by 3.3% on a unit basis and increased by 0.3% on USD basis, reaching USD 3,1 billion on USD basis. The rate of import to the total pharmaceutical market is 24% on a unit basis and 57% on USD basis.

According to IMS Health data, the sector grew by 3.92% on a unit basis and shrunk by 0.3% on USD basis, resulting in USD 7.2 billion in 2017. The total pharmaceutical market reached TL 20,50 billion, with a growth of 26.4%.


(*) “Surplus Goods” are included in the value in units but not included in the value in TL depending on the change in the calculation method of the IMS.

Market distribution according to drug segments in our country in 2017 took place on unit and TL/USD basis as follows. On both unit and TL/USD basis, Nutrition & Metabolism segment has the biggest share.



Source: IMS Health Free +Tender Dataview



We exist to offer innovative and diversified rang of products with a high quality experience enabling healthy life opportunity to be available to everyone on a global scale.


To become the first choice by creating robust pharmaceutical brands in the areas we compete in.


• Resilience

• Ownership 

• Innovation and development

• Trustworthiness

• Human focus

• Teamwork




DEVA quality reflects two fundamental principles of CARE and INNOVATION.

We care for our patients, customers, partners, employees and environment in which we manufacture our products. In taking care we provide a secure and ethical supply of products to underpin the DEVA brand and reputation.

We innovate our products, processes and management practices to enable our company to continously improve our service, our market share and to hold a competitive advantage. Through our innovative approaches we are able to maximiseshare holder investments.


DEVA quality culture is founded upon the concept of “Right first time”. Each and every employee at DEVA adopts it as a principle to ensure patient safety and excellence in operations.

DEVA quality culture starts with product research and development and covers all processes from production through to our distribution networks.


DEVA quality management system ensures our care and innovative principles link directly to our quality culture. Our quality management system provides a framework of operational procedures that bring consistency and best practice to all of our manufacturing sites and also satisfies legal requirements and international levels of Good Manufacturing Practice (GMP). Throughout the quality management system risk managment techniques and pragmatic application exists.


DEVA is driven by people with passion and understanding. In all aspects of our products DEVA employees strive for improvement and to seek out competitive advantage in both Turkey and International markets. Our people are dedicated and determined to match the challenges facing the pharmaceutical markets.




Philipp Haas

President of the Board of Directors and CEO

Philipp Haas, Chairman of Board of Directors and CEO of DEVA Holding, took his MBA with a major in banking from St. Gallen Economy, Law and Business Administration University. He is fluent in German, English, French, Spanish, Portuguese, Italian and Turkish. Philipp Haas who has been working as investment advisor and manager since 1992 has a broad experience in the Eastern European countries and Turkey in particular. Having taken part in several restructuring projects in Ukraine and Turkey, Philipp Haas acted as member of several board of directors as representative of foreign corporate investors during the 90s, and Rogan Brewery of Ukraine and Net Holding of Turkey may be mentioned among others. Philipp Haas who has had a vast experience in pharmaceutical industry has provided funds with pharmaceutical industry advisory and helped them direct their investments into Eastern Europe. These included Slovakopharma which changed its name to Zentiva subsequently. Currently serving as Chairman of Board of Directors of EastPharma Ltd., DEVA Holding, Saba İlaç Sanayi ve Ticaret A.Ş., New Life Yaşam Sigorta A.Ş., EastPharma İlaç Üretim Pazarlama San. ve Tic. A.Ş. and a member of Board of Directors at EastPharmaSarl. He also serves as a director in Devatis Limited, Devatis Gmbh, Devatis A.G and Devatis Inc. Philipp Haas is Vice Chairman of the Board of Directors at Pharmaceutical Manufacturers Association of Turkey (TISD).


Mesut Çetin

Deputy Chairman of the BOD and CFO

The Deputy Chairman of the Board of Directors and CFO of DEVA Holding, Mesut Çetin worked as director responsible for operations within GEM Global Equities Management S.A. 2005 and 2007 and has served in various positions within the same group as analyst, trader and project manager since 1999.Mesut Çetin is the member of the BOD in EastPharma Ltd. Saba İlaç Sanayi ve Ticaret A.Ş. He also performs the duty of CFO in various companies within the group. Mesut Çetin is the graduate of Mathematics in Boğaziçi University and continues the EMBA program in Koç University. 


Güneş Ufuk

Member of the Board of Directors

Güneş Ufuk, an independent director of the Board of Directors of DEVA Holding, had worked within the sales and marketing departments of a number of Swiss companies after studying at the faculty of Business of Administration, St. Gallen University in Switzerland. He also worked in top management functions at Kemer Golf&Country Club, Superonline and YKS (which is also an affiliate of the Çukurova Group of Companies).

Upon putting an end to his professional career at Kemer Golf & Country Club while working as in General Manager Position, Ufuk started a new career as a consultant. He had worked as an Executive Officer and Consultant within MCT Company for over 6 years; and then founded k2 Consulting Company in April 2010 and provided various companies in Turkey with Management Consultation service as a Trainer and Speaker. By providing services with his k2 Consultancy team to 100+ leading companies operating in various areas in Turkey, Ufuk has become an expert in the fields of “Sales and Marketing”, “Leadership” and “Strategy”.

He is one of the founding partners of K2C Consulting Company which was founded in 2015, and continues his operations at K2C Consulting Company.


Ayşecik Haas

Member of the Board of Directors

Being the Non-Executive Member of the Board of Directors of DEVA Holding, Ayşecik Haas completed her license degree in Electrical-Electronic Engineering in Doğu Akdeniz University after graduating Ankara Private Yükseliş College in 1991, then took her master degree in Economics branch in Texas Tech University. 

Having commenced the work life at various positions relating to engineering in Emek Elektrik and Beko Elektronik in Turkey, Ayşecik Haas worked in finance sector in New York after taking Economy Master degree after which she worked as investment specialist in Hattat Holding for a short period of time. Having commenced to perform as General Manager of NAR Group, a media company, in 2008, Ayşecik Haas is currently continuing this task.


Tuncay Cem Akkuş

Member of the Board of Directors

Independent Member of the Board of Directors, has a  bachelor’s degree in the department of Electric-Electronical Engineering of East Mediterranean University.

He started his career with General Directorate of PTT as system engineer and after a short time he worked in the telecommunication sector.  In this sector, he worked with, respectively, Siemens A.Ş, Sabancı Telekom, Global İletişim, Turkcell Superonline and finally Millenicom as a manager on engineering and infrastructure project in operation department.


  Our aim is to ensure environmental regulations, occupational regulations, local    requirements and stakeholder expectations;

  To ensure that we keep under control the effects of our productions of health-     safety-environment and to use appropriate Technologies and to endeavor to not occur accidents and occupational diseases.

  To ensure that we give to our workers and stakeholders educations to raise their health-safety-environment behaviour.

  To ensure sustainability environment that we give to our workers and  stakeholders educations to raise their health-safety-environment behaviour.

 Our aim is to ensure that we are the model firm about health-safety-environment.

 To undertake that this policy is revised to prevent hazards which cause accidents and occupational diseases with our systems.

                                     Philipp Haas                                                                    Mesut Çetin  

C                      Chairman of the Board of Directors and CEO                        Deputy Chairman of the BOD and CFO